MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Lista de Ações・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Fechado

4.77 -0.83

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.74

Máximo

4.79

Indicadores-chave
By Trading Economics
Rendimento	-10M -7.7M
Vendas	-10M 529K
Margem de lucro	-1,463.516
Funcionários	44
EBITDA	-10M -7.7M

Dividendos
By Dow Jones
Próximos Ganhos	26 de mar. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	28M 908M
Abertura anterior	5.6
Fecho anterior	4.77

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

3.255 / 3.365 Suporte e Resistência

Arbutus Biopharma Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jan. de 2026, 22:45 UTC

Grandes Movimentos do Mercado

GH Research Shares Up, Plans to Provide Update on New Drug Application

4 de jan. de 2026, 23:50 UTC

Conversa de Mercado

Notícias Principais

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

4 de jan. de 2026, 23:50 UTC

Conversa de Mercado

Notícias Principais

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

4 de jan. de 2026, 23:41 UTC

Conversa de Mercado

Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

4 de jan. de 2026, 23:40 UTC

Conversa de Mercado

Notícias Principais

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

4 de jan. de 2026, 23:35 UTC

Conversa de Mercado

Notícias Principais

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

4 de jan. de 2026, 23:19 UTC

Conversa de Mercado

Notícias Principais

Global Energy Roundup: Market Talk

4 de jan. de 2026, 23:19 UTC

Conversa de Mercado

Notícias Principais

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

4 de jan. de 2026, 23:17 UTC

Notícias Principais

Spot Gold Rises 0.8% to $4,365.24/oz

4 de jan. de 2026, 23:16 UTC

Notícias Principais

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

4 de jan. de 2026, 23:14 UTC

Notícias Principais

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

4 de jan. de 2026, 23:13 UTC

Notícias Principais

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

4 de jan. de 2026, 23:12 UTC

Conversa de Mercado

Notícias Principais

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

4 de jan. de 2026, 22:37 UTC

Conversa de Mercado

Notícias Principais

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

4 de jan. de 2026, 21:00 UTC

Ganhos

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

4 de jan. de 2026, 20:49 UTC

Conversa de Mercado

Notícias Principais

Global Energy Roundup: Market Talk

4 de jan. de 2026, 20:49 UTC

Conversa de Mercado

Notícias Principais

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

3 de jan. de 2026, 18:59 UTC

Notícias Principais

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3 de jan. de 2026, 17:42 UTC

Notícias Principais

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

3 de jan. de 2026, 17:40 UTC

Notícias Principais

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3 de jan. de 2026, 16:10 UTC

Notícias Principais

What Maduro's Capture Means for Chevron Stock -- Barrons.com

3 de jan. de 2026, 15:53 UTC

Notícias Principais

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 de jan. de 2026, 15:03 UTC

Notícias Principais

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 de jan. de 2026, 14:10 UTC

Notícias Principais

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 de jan. de 2026, 12:16 UTC

Notícias Principais

U.S. Captures Maduro, Trump Says -- Barrons.com

3 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

3 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Ganhos

Auto & Transport Roundup: Market Talk

3 de jan. de 2026, 00:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Research Reports -- Barrons.com

2 de jan. de 2026, 22:13 UTC

Conversa de Mercado

Ganhos

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

Comparação entre Pares

Variação de preço

Arbutus Biopharma Corp Previsão

Consenso de Avaliação

By TipRanks

0 ratings

Comprar

Manter

Vender

Com base em 0 analistas que deram avaliações de ações para Arbutus Biopharma Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

3.255 / 3.365Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.